pioglitazone has been researched along with Cardiac Remodeling, Ventricular in 14 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because proinflammatory cytokines play a critical role in left ventricular (LV) remodeling after myocardial infarction (MI), we examined the effects of pioglitazone treatment in an experimental model of chronic heart failure." | 7.71 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. ( Egashira, K; Hayashidani, S; Ikeuchi, M; Ishibashi, M; Kubota, T; Shiomi, T; Suematsu, N; Takeshita, A; Tsutsui, H; Wen, J, 2002) |
| "In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity." | 5.14 | Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. ( Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW, 2009) |
| " Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovascular injury." | 3.74 | Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008) |
| " Therefore, we examined the effect of pioglitazone, a PPARgamma agonist, on chronic left ventricular remodeling after experimental myocardial infarction (MI) in mice." | 3.72 | Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. ( Bauersachs, J; Bayer, B; Ertl, G; Frantz, S; Galuppo, P; Hu, K; Schmidt, I; Strotmann, J; Widder, J; Witzel, CC, 2004) |
| " Because proinflammatory cytokines play a critical role in left ventricular (LV) remodeling after myocardial infarction (MI), we examined the effects of pioglitazone treatment in an experimental model of chronic heart failure." | 3.71 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. ( Egashira, K; Hayashidani, S; Ikeuchi, M; Ishibashi, M; Kubota, T; Shiomi, T; Suematsu, N; Takeshita, A; Tsutsui, H; Wen, J, 2002) |
| "Pioglitazone treatment improved survival, reduced PASP, muscularization of small pulmonary arteries, and medial wall thickness." | 1.43 | Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension. ( Baldus, S; Behringer, A; Berghausen, EM; Blaschke, F; Caglayan, E; Er, F; Gassanov, N; Kappert, K; Odenthal, M; Rosenkranz, S; Ten Freyhaus, H; Trappiel, M; Wellnhofer, E, 2016) |
| "Telmisartan is an angiotensin II receptor blocker, which acts as a partial agonist of peroxisome proliferator activator receptor-γ (PPAR-γ)." | 1.38 | Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia. ( Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Ogawa, M; Shimizu, T; Suzuki, J; Takayama, K; Watanabe, R, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Konegawa, Y | 1 |
| Kuwahara, T | 1 |
| Jo, JI | 1 |
| Murata, K | 1 |
| Takeda, T | 1 |
| Ikeda, T | 1 |
| Minatoya, K | 1 |
| Masumoto, H | 1 |
| Tabata, Y | 1 |
| Chen, WJ | 1 |
| Greulich, S | 1 |
| van der Meer, RW | 2 |
| Rijzewijk, LJ | 2 |
| Lamb, HJ | 2 |
| de Roos, A | 2 |
| Smit, JW | 2 |
| Romijn, JA | 2 |
| Ruige, JB | 1 |
| Lammertsma, AA | 2 |
| Lubberink, M | 2 |
| Diamant, M | 2 |
| Ouwens, DM | 1 |
| Yu, Y | 1 |
| Xue, BJ | 1 |
| Wei, SG | 1 |
| Zhang, ZH | 1 |
| Beltz, TG | 1 |
| Guo, F | 1 |
| Johnson, AK | 1 |
| Felder, RB | 1 |
| Behringer, A | 1 |
| Trappiel, M | 1 |
| Berghausen, EM | 1 |
| Ten Freyhaus, H | 1 |
| Wellnhofer, E | 1 |
| Odenthal, M | 1 |
| Blaschke, F | 1 |
| Er, F | 1 |
| Gassanov, N | 1 |
| Rosenkranz, S | 1 |
| Baldus, S | 1 |
| Kappert, K | 1 |
| Caglayan, E | 1 |
| Kamimura, D | 1 |
| Uchino, K | 1 |
| Ishigami, T | 1 |
| Hall, ME | 1 |
| Umemura, S | 1 |
| Ye, Y | 1 |
| Lin, Y | 1 |
| Perez-Polo, JR | 1 |
| Birnbaum, Y | 1 |
| de Jong, HW | 1 |
| Bax, JJ | 1 |
| Kamp, O | 1 |
| Paulus, WJ | 1 |
| Heine, RJ | 1 |
| Tian, YQ | 1 |
| Li, SS | 1 |
| Su, XD | 1 |
| Zhang, GZ | 1 |
| Zhao, JJ | 1 |
| Li, GW | 1 |
| Wang, L | 1 |
| Morrow, JP | 1 |
| Katchman, A | 1 |
| Son, NH | 1 |
| Trent, CM | 1 |
| Khan, R | 1 |
| Shiomi, T | 2 |
| Huang, H | 1 |
| Amin, V | 1 |
| Lader, JM | 1 |
| Vasquez, C | 1 |
| Morley, GE | 1 |
| D'Armiento, J | 1 |
| Homma, S | 1 |
| Goldberg, IJ | 1 |
| Marx, SO | 1 |
| Nagashima, A | 1 |
| Watanabe, R | 1 |
| Ogawa, M | 1 |
| Suzuki, J | 1 |
| Masumura, M | 1 |
| Hishikari, K | 1 |
| Shimizu, T | 1 |
| Takayama, K | 1 |
| Hirata, Y | 1 |
| Nagai, R | 1 |
| Isobe, M | 1 |
| Tsutsui, H | 1 |
| Hayashidani, S | 1 |
| Suematsu, N | 1 |
| Ikeuchi, M | 1 |
| Wen, J | 1 |
| Ishibashi, M | 1 |
| Kubota, T | 1 |
| Egashira, K | 1 |
| Takeshita, A | 1 |
| Frantz, S | 1 |
| Hu, K | 1 |
| Widder, J | 1 |
| Bayer, B | 1 |
| Witzel, CC | 1 |
| Schmidt, I | 1 |
| Galuppo, P | 1 |
| Strotmann, J | 1 |
| Ertl, G | 1 |
| Bauersachs, J | 1 |
| Rodriguez, WE | 1 |
| Joshua, IG | 1 |
| Falcone, JC | 1 |
| Tyagi, SC | 1 |
| Nakamura, T | 1 |
| Yamamoto, E | 1 |
| Kataoka, K | 1 |
| Yamashita, T | 1 |
| Tokutomi, Y | 1 |
| Dong, YF | 1 |
| Matsuba, S | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pioglitazone and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes.
Topics: Activins; Adipose Tissue; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Cardiomyop | 2013 |
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 2009 |
12 other studies available for pioglitazone and Cardiac Remodeling, Ventricular
| Article | Year |
|---|---|
Pioglitazone-incorporated microspheres targeting macrophage polarization alleviates cardiac dysfunction after myocardial infarction.
Topics: Animals; Delayed-Action Preparations; Macrophages; Microspheres; Myocardial Infarction; Myocardium; | 2022 |
Activation of central PPAR-γ attenuates angiotensin II-induced hypertension.
Topics: Angiotensin II; Anilides; Animals; Blood Pressure; Brain; Disease Models, Animal; Hypertension; Infu | 2015 |
Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Topics: Animals; Arterial Pressure; Cardiovascular Agents; Disease Models, Animal; Fibrosis; Heart Ventricle | 2016 |
Activation of Peroxisome Proliferator-activated Receptor γ Prevents Development of Heart Failure With Preserved Ejection Fraction; Inhibition of Wnt-β-catenin Signaling as a Possible Mechanism.
Topics: Animals; beta Catenin; Collagen Type I; Disease Models, Animal; Disease Progression; Fibrosis; Heart | 2016 |
Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone.
Topics: Administration, Oral; Animals; Body Weight; Coronary Vessels; Data Interpretation, Statistical; Deca | 2008 |
Effects of pioglitazone on high-fat-diet-induced ventricular remodeling and dysfunction in rats.
Topics: Animals; Blood Pressure; Diet, High-Fat; Echocardiography; Fatty Acids, Nonesterified; Hypertrophy, | 2012 |
Mice with cardiac overexpression of peroxisome proliferator-activated receptor γ have impaired repolarization and spontaneous fatal ventricular arrhythmias.
Topics: Action Potentials; Animals; Calcium; Connexin 43; Death, Sudden, Cardiac; Disease Models, Animal; El | 2011 |
Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antihypertensive Agents; Ben | 2012 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
Topics: Administration, Oral; Animals; Aspartate Aminotransferases; Blood Glucose; Cytokines; Disease Models | 2002 |
Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction.
Topics: Animals; Aorta; Blood Glucose; Body Weight; Chronic Disease; Collagen; Coronary Vessels; Cytokines; | 2004 |
Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Type 2; Dietary Fats; Dose-Response Relationship, Drug; Energy Intake; H | 2006 |
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2008 |